Jefferies Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Jefferies Financial Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-700	Closed	-$17.6K	–	1718
2025 Q4	$17.6K	Hold	700	–	–	﹤0.01%	1802
2025 Q3	$15.8K	Hold	700	–	–	﹤0.01%	1415
2025 Q2	$12.1K	Hold	700	–	–	﹤0.01%	1236
2025 Q1	$15.3K	Hold	700	–	–	﹤0.01%	1546
2024 Q4	$22.3K	Sell	700 -9,500	-93%	-$286K	﹤0.01%	1526
2024 Q3	$294K	Hold	10,200	–	–	﹤0.01%	1120
2024 Q2	$391K	Hold	10,200	–	–	﹤0.01%	1034
2024 Q1	$600K	Buy	10,200 +8,200	+410%	+$523K	0.01%	999
2023 Q4	$120K	Hold	2,000	–	–	﹤0.01%	1527
2023 Q3	$76.1K	Sell	2,000 -130,000	-98%	-$5.71M	﹤0.01%	1482
2023 Q2	$12M	Buy	132,000 +2,000	+2%	+$173K	0.11%	171
2023 Q1	$8.57M	Buy	+130,000	New	+$7.5M	0.07%	244

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's APLS Position: Q2 2026 in Review

Jefferies Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 219,000 shares — an estimated $8.81M sold.

Jefferies Financial Group first reported a position in APLS in Q1 2023 and held it in 13 quarters. The position peaked at $13.1M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Jefferies Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jefferies Financial Group sold 219,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.81M.
Jefferies Financial Group first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 13 quarters.
Jefferies Financial Group's Apellis Pharmaceuticals position peaked at $13.1M in Q1 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.